Johnson & Johnson is in advanced talks to buy Ollin Biosciences, a privately held developer of eye-disease drugs, for as much as $3.4 billion, people familiar with the matter said, a move that would push the health-care giant deeper into retinal medicine.
Under the terms being discussed, J&J would pay Ollin investors about $2.2 billion in cash upfront and up to $1.2 billion more tied to development milestones, the people said. An agreement could be announced as soon as Monday, though the negotiations could still fall apart. A British business newspaper first reported the talks Sunday. J&J and Ollin did not comment.
Going after the retina
Ollin, backed by ARCH Venture Partners and Mubadala Capital, is developing OLN324, an antibody designed to block two proteins, VEGF and Ang2, that drive abnormal blood vessel growth and leakage in the eye. The company has said it planned to begin late-stage trials in diabetic macular edema and wet age-related macular degeneration in the second half of 2026. It raised $330 million in June to pay for those studies.
Its pipeline also includes OLN102, a bispecific antibody targeting two receptors involved in thyroid eye disease and Graves disease.
The retinal market is dominated by injected drugs such as Regeneron and Bayer products and Roche, whose Vabysmo already hits the same two targets. J&J sells contact lenses and surgical vision equipment but has little presence in prescription retinal drugs, so a deal would give it a late-stage entry rather than starting from scratch.
A record year for biotech buyouts
The talks come in a record year for biotech takeovers. Investment bank Stifel has counted 46 acquisitions of biotech companies valued at more than $1 billion so far this year, above the previous annual high of 35. Recent examples include AstraZeneca and its roughly $10 billion offer for Rhythm Pharmaceuticals and argenx agreeing to buy Unnatural Products for up to $1.15 billion.
The structure under discussion, with a large slice of value held back for milestones, has become standard for drugs that have not yet finished pivotal trials. It lets the buyer cap what it pays if the science disappoints while giving venture backers a quick return on a company that has not had to test the public markets.
Section: More Irmo SC business news
Irmo business profiles
Filed under: Irmo SC Business News